Papers - TANAKA Hisashi
-
Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.
Hisashi Tanaka, Atsushi Horiike, Toshio Sakatani, Ryota Saito, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Takeshi Horai, Makoto Nishio
Anti-cancer drugs 26 ( 5 ) 573 - 578 2015.6
-
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Atsushi Horiike, Nobuyuki Yamamoto, Hisashi Tanaka, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Akira Ono, Tateaki Naito, Haruyasu Murakami, Takeshi Horai, Makoto Nishio
Anticancer research 34 ( 4 ) 1975 - 1981 2014.4
-
The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review.
Hisashi Tanaka, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Kunihiko Nakamura, Akihito Hayashi, Akira Kurose, Ken Okumura, Shingo Takanashi
OncoTargets and therapy 7 87 - 90 2013.12
-
Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma.
Hisashi Tanaka, Kiyoshi Tone, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Hideyuki Nakagawa, Shingo Takanashi, Ken Okumura, Akira Kurose
Lung cancer (Amsterdam, Netherlands) 80 ( 3 ) 289 - 292 2013.6
-
A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
Hisashi Tanaka, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Michiko Shimada, Akira Kurose, Shingo Takanashi, Ken Okumura
BMC cancer 12 558 - 558 2012.11